Moreover, the evidence that PDK1 deletion with GSK2334470 re-sensitized BC cells to PI3 Kα inhibitor BYL719 [83] and CDK4/6 inhibitors, respectively [80], was encouraging enough to merit further clinical trials of GSK2334470 in patients with metastatic or acquired resistant BCs. Here, CDK4 is linked to breast cancer.